AnaptysBio Inc logo

ANAB - AnaptysBio Inc Share Price

$14.1 0.6  4.4%

Last Trade - 9:00pm

Sector
Healthcare
Size
Small Cap
Market Cap £297.0m
Enterprise Value £-3.85m
Revenue £6.46m
Position in Universe 2824th / 6310
Bullish
Bearish
Unlock ANAB Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ANAB Revenue Unlock ANAB Revenue

Net Income

ANAB Net Income Unlock ANAB Revenue

Normalised EPS

ANAB Normalised EPS Unlock ANAB Revenue

PE Ratio Range

ANAB PE Ratio Range Unlock ANAB Revenue

Dividend Yield Range

ANAB Dividend Yield Range Unlock ANAB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ANAB EPS Forecasts Unlock ANAB Revenue
Profile Summary

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated November 16, 2005
Public Since January 26, 2017
No. of Shareholders: 14
No. of Employees: 89
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 27,265,262
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ANAB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ANAB
Upcoming Events for ANAB
Monday 1st June, 2020 Estimate
Q1 2020 AnaptysBio Inc Earnings Release
Similar to ANAB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.